The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER2+) cancer.
Amy Jo Chien
Research Funding - Merck
Thach-Giao Truong
No relevant relationships to disclose
Michelle E. Melisko
Research Funding - Merck
Mark M. Moasser
No relevant relationships to disclose
Robin Katie Kelley
Research Funding - Merck
Michael Korn
No relevant relationships to disclose
Andrew H. Ko
No relevant relationships to disclose
Norma Pantoja
No relevant relationships to disclose
Anne Reinert
No relevant relationships to disclose
Jennifer A. Grabowsky
No relevant relationships to disclose
Mark Jesus M Magbanua
No relevant relationships to disclose
Hope S. Rugo
Research Funding - Merck
Pamela N. Munster
Consultant or Advisory Role - Merck (I,U)
Research Funding - Merck (B)